Evidence map›Paper›PMID 42243792›Full record

ArticleJournal of nanobiotechnology2026

Acid-enhanced drinkable hydrogel co-delivering riboflavin-loaded nanozymes for orchestrated inflammation-immune modulation and redox homeostasis in colitis therapy.

Wenting Pan, Ying Song, Yuchen Wang, Sakandar Abbas, YiChao Jing, Haibin Huang, Yuanzhe Li, Wang Ma, Jianguo Feng, Huan Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenting Pan *Department of Stomatology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Ying Song *Oncology department, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Yuchen Wang *School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Sakandar AbbasOncology department, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
YiChao JingDepartment of Stomatology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Haibin HuangOncology department, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Yuanzhe LiDepartment of Pediatrics, Children's Hospital Affiliated of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Wang MaOncology department, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan, China. doctormawang@126.com.
Jianguo FengAnesthesiology and Critical Care Medicine Key Laboratory of Luzhou, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, China. fengjianguo@swmu.edu.cn.
Huan ZhaoOncology department, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan, China. zhaohuan1988@zzu.edu.cn.

Funding

Central Plains Leading Talent Program (Science and Technology Innovation) of Henan Province 264200510003Luzhou Science and Technology Program 2025RCX002National Natural Science Foundation of China 82302431
6 · The paper itself

Abstract

Conventional inflammatory bowel disease therapies are limited by inefficient colon-targeted delivery, systemic side effects, and a failure to rectify the underlying oxidative stress and immune dysregulation. Riboflavin (RAF) possesses ideal antioxidant and immunomodulatory properties for colitis therapy but suffers from rapid proximal absorption. While acid-degradable metal-organic framework (MOF) nanozymes can co-deliver RAF and catalytically eliminate reactive oxygen species (ROS), they lack colon-retentive capacity. To overcome these barriers, we engineered an acid-enhanced, drinkable hydrogel for the coordinated delivery of riboflavin-loaded Pt-MOF nanozymes (RAF@Pt-ZIF@CS, RPZCS). This food-grade sodium alginate system undergoes a drinkable sol-to-mucoadhesive gel transition triggered specifically by the acidic colonic microenvironment (pH 5.0-6.0). The subsequent acid-etching of the Pt-MOF framework enables spatiotemporally coupled burst release of RAF and Pt ions. In a DSS-induced colitis model, RPZCS demonstrated superior lesion retention and exerted comprehensive therapeutic effects. It robustly scavenged ROS via the SCAD-DJ-1-KEAP1-Nrf2 pathway, suppressed pro-inflammatory M1 macrophage polarization, rebalanced the Treg/Th17 immune axis and pro-/anti-inflammatory cytokines, enhanced mucosal/epithelial barrier integrity and restore gut microbiota. Furthermore, RPZCS favorably remodeled the gut microbiota structure. A 14-day repeated-dose toxicity study confirmed its "drinkable-grade" safety. Collectively, this acid-responsive hydrogel platform achieves orchestrated inflammation-immune modulation and redox homeostasis, offering a safe, effective, and highly compliant oral strategy for targeted colitis therapy.

Indexed as

ColitisHydrogelsRiboflavinAnimalsHomeostasisInflammationMaleMiceMice, Inbred C57BLOxidation-ReductionOxidative StressReactive Oxygen SpeciesHydrogelsReactive Oxygen SpeciesRiboflavinAcid-responsive hydrogel platformColitis therapyRedox homeostasisRiboflavin

Identifiers

PMID42243792
PMCPMC13455327

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.